Biomarker and Diagnostics Strategy

This is where precision medicine starts – whether you’re trying to find the right tools to uncover new biomarkers, identify CDx partners, launch an IVD, or understand how your assay will fit into the clinical journey, DeciBio has you covered. Nobody knows biomarkers and CDx better than DeciBio.

Our Experts

Andrew Aijian

Stephane Budel

David Cavanaugh

David Cavanaugh

Schedule a Call

Related Client Results

All Client Results

Pharma & Biotech

Clinical, Genomic, and Pathology Real-World Data (RWD) Market Landscape Assessment

A real-world data (RWD) provider wanted to identify key use cases, unmet needs, and future opportunities in the RWD market, with a particular focus on clinical, genomic, and pathology RWD and biopharma users.

Voice-of-Customer Research

Pricing Strategy

Competitive Analysis

Clinical Diagnostics

RNA-based Oncology Biomarker Market Landscape

A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings

Voice-of-Customer Research

Competitive Analysis

Biomarker and Diagnostics Strategy

Product Specification Mapping

Pharma & Biotech

Cell and Gene Therapy Service Market Opportunity Assessment

A startup wanted to understand how customers could use its cutting-edge technology and which applications to target for further development

Voice-of-Customer Research

Cell Line Market 5-Year Forecast

A large life science tools provider was interested in characterizing the genome engineering and engineered cell line market to identify potential opportunities to participate in the space

Voice-of-Customer Research

Pharma & Biotech

Cell and Gene Therapy Services Landscape Assessment

A top-10 scientific service provider wanted to quantify the size of the CGT services market and understand trends within

No items found.

Pharma & Biotech

Early-Stage Cancer Biomarker Testing and Treatment Landscape Assessment

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

Competitive Analysis

Voice-of-Customer Research

Precision Medicine is evolving at a rapid pace

Discover how we can help